期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 85, 期 4, 页码 358-360出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0609.2010.01497.x
关键词
WT1 peptide vaccine; CML; immunotherapy; Imatinib
类别
资金
- Ministry of Education, Science, Sports, Culture and Technology
- Ministry of Health, Labour, and Welfare, Japan
- Grants-in-Aid for Scientific Research [21591205] Funding Source: KAKEN
How to treat CML patients who are resistant to inhibitors of BCR-ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib-treated CML in which intradermally administered WT1 peptide vaccine elicited WT1-specific immune responses and the resultant reduction in the persistent residual disease in co-administration of Imatinib. BCR-ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR-ABL mRNA levels was associated with the increase in frequency of WT1-specific cytotoxic T lymphocytes, notably effector-memory type of that, in the patient's peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure-oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据